Zacks Investment Research
30 Oct 2026, 14:55 UTC · 1h ago
Impact · against what's priced in
The news is not a catalyst for Vaxcyte. The reported price targets and positive earnings revisions are consensus data points that are already reflected in the current stock price.
No priced-in read yet
What the story claims
2 claims · scored −1 bearish … +1 bullish · 0 new · 2 priced in
Wall Street analysts have set a mean short-term price target of $117.3 for Vaxcyte (PCVX).
Priced inanalysis of existing analyst price targets
So whatThis consensus target implies an 87.4% gain from the last close of $62.61.
More positive than 92% of claims this week
Analysts are showing a positive trend in earnings estimate revisions for Vaxcyte.
Continue reading
5 related stories
While the article highlights an 87.4% upside based on a mean target of $117.3, this is based on existing analyst consensus and public earnings revisions rather than new fundamental developments.
Read from the article alone
Scored by the NIS engine · methodology.
Priced inanalysis of existing earnings revisions
So whatConsistent upward revisions typically lead to EPS beats in the upcoming reporting cycle.
More positive than 76% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company has a strong average analyst price target indicating significant upside potential and positive earnings estimate revisions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
1h ago
−2.3%
$61.16 vs $62.61 close before publication (Oct 29) · not market-adjusted
PCVX chart →
